SWEDISH ORPHAN BIOVITRUM

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2010-01-01

Employees: -

Market Cap: $10.7B

Website: http://www.sobi.com/

Clinical Trials

Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support

Phase 1

Completed

Conditions: Lymphoma
Leukemia
Myeloma

Interventions: Drug: Palifermin 2 x 180 μg/kg/day
Drug: Palifermin 6 x 60 μg/kg/day
Radiation: radiotherapy
Drug: Chemotherapy

First Posted Date: 2003-10-08

Last Posted Date: 2014-10-24

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 25

Registration Number: NCT00070616

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy